EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Michael I Sponfeldner iD, Pauline Dürr iD, Phyllis Lensker iD, Katja Gessner iD, Lisa Cuba iD, Rainer Fietkau iD, Markus F Neurath iD, Bernd Wullich iD, Marianne Pavel iD, Carola Berking iD, Matthias W Beckmann iD, Andreas Mackensen iD und 2 weitere

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70166 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Michael I Sponfeldner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Antineoplastic Agents, Kidney, Kidney Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function. Nonrecognition of PW can lead to dose reductions, interruptions, or discontinuations of OAT. The extent and incidence of PW has so far not been studied for a broad set of OAT in clinical routine. In this retrospective, multicenter cohort study, 694 AMBORA patients newly started on OAT were assessed for eligibility. eGFR values were compared between baseline and within 30 days of treatment. OAT were separated into the groups unlikely causing and likely causing/with proven PW. The usage of cystatin C measurements as an alternative method for assessing kidney function was evaluated. A total of 238 patients received 38 OAT likely causing PW/with proven PW. In this group, eGFR decreased significantly (−6.8 ml/min, p < 0.001). In 17.2% of these patients, eGFR decreased by ≥20 ml/min. Significant decreases in eGFR were observed for patients receiving, for example, abemaciclib, ribociclib, and osimertinib. Cystatin C measurements were not performed in 95.8% of the patients. In the group of 67 patients receiving OAT unlikely causing PW, there was no significant change in eGFR. In clinical routine, multiple OAT associated with PW are prescribed. A very low rate of usage of creatinine‐independent methods for assessing kidney function (cystatin C) indicates that further training of oncologists is required on OAT‐induced PW to further improve patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerular Filtration RateAntineoplastic AgentsKidneyKidney DiseasesHumansMaleRetrospective StudiesFemaleMiddle AgedAgedAdministration, OralIncidenceCreatinineCystatin CCohort StudiesAdultKidney Function TestsAged, 80 and over

Substanzen

Antineoplastic AgentsCreatinineCystatin C

Autor:innen und Institutionen

  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Pharmacy Department, Erlangen University Hospital and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Comprehensive Cancer Center Erlangen-EMN, Uniklinikum Erlangen, Erlangen, Germany.
  • Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
  • Department of Radiation Oncology, Uniklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Medicine 1, Gastroenterology, Pneumology and Endocrinology, Uniklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Michael I Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W Beckmann, Andreas Mackensen, Frank Dörje, Martin F Fromm

Zitieren

APA

Sponfeldner, M. I., Dürr, P., Lensker, P., Gessner, K., Cuba, L., Fietkau, R., Neurath, M. F., Wullich, B., Pavel, M., Berking, C., Beckmann, M. W., Mackensen, A., Dörje, F., & Fromm, M. F. (2026). Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70166

Vancouver

Sponfeldner MI, Dürr P, Lensker P, Gessner K, Cuba L, Fietkau R, et al. Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70166

BibTeX
@article{Sponfeldner2026,
  author = {Sponfeldner, Michael I and Dürr, Pauline and Lensker, Phyllis and Gessner, Katja and Cuba, Lisa and Fietkau, Rainer and Neurath, Markus F and Wullich, Bernd and Pavel, Marianne and Berking, Carola and Beckmann, Matthias W and Mackensen, Andreas and Dörje, Frank and Fromm, Martin F},
  title = {Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70166}
}
Kostenlos starten →